GURU.Markets stock price, segment price, and overall market index valuation
The company's share price MacroGenics Inc.
MacroGenics is a biotech company developing cancer treatments. Its stock price is highly volatile and dependent on clinical trial results. The chart reflects the binary risks and the enormous potential of its research platform for creating new antibodies.
Share prices of companies in the market segment - Breast cancer
MacroGenics is a biopharmaceutical company developing innovative monoclonal antibodies for cancer treatment, including MARGENZA for breast cancer. We classify this drug under "Breast Cancer." The chart below shows the overall dynamics of this important oncology segment.
Broad Market Index - GURU.Markets
MacroGenics is an oncology company developing antibody-based drugs for the treatment of cancer, particularly breast cancer. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how MacroGenics shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
MGNX - Daily change in the company's share price MacroGenics Inc.
For MacroGenics, Inc., an oncology company, daily price change is a measure of extreme volatility. It reflects investor reaction to clinical trial news and is a critical parameter for risk assessment formulas on the System.GURU.Markets platform.
Daily change in the price of a set of shares in a market segment - Breast cancer
MacroGenics, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with MGNX's performance, which is dependent on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
MacroGenics is a biotech company with a broad pipeline in immuno-oncology. Its shares react to news on numerous clinical programs. This complex, multi-factorial dynamic contributes uniquely to the overall volatility of the healthcare sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization MacroGenics Inc.
MacroGenics, Inc.'s year-over-year performance tells the story of its oncology portfolio. Its market capitalization over the past 12 months reflects both sales of its approved breast cancer drug and, more importantly, progress in clinical trials of its innovative bispecific antibodies and other immuno-oncology candidates.
Annual dynamics of market capitalization of the market segment - Breast cancer
MacroGenics, Inc. is a biotech company developing immunotherapies for cancer treatment. Its platform enables the creation of more effective antibodies. Its stock price reflects both the potential of its scientific platform and the risks associated with clinical trials, which is typical for the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
MacroGenics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization MacroGenics Inc.
MacroGenics develops innovative antibodies for cancer treatment. Its monthly performance reflects both sales of its commercial drug, Margenza, and, to a greater extent, news from its extensive clinical pipeline. New development data is the main driver of volatility.
Monthly dynamics of market capitalization of the market segment - Breast cancer
MacroGenics is a biotech company developing innovative antibody-based drugs for cancer treatment. Its platform enables the creation of more effective and safer oncology drugs. The graph below shows the dynamics of the biotech sector, where immuno-oncology remains a key focus.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
MacroGenics is a biotech company whose stock is preoccupied with the results of clinical trials. Its monthly performance is completely disconnected from the market and driven by drug development news. The chart clearly illustrates that for such companies, trial data is more important than the overall economic situation.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization MacroGenics Inc.
MacroGenics, a biotech company developing antibody-based drugs for cancer treatment, is experiencing high volatility. Weekly stock performance is driven by news about clinical trials, regulatory decisions, and partnerships with major pharmaceutical companies, reflecting the risks and potential of oncology.
Weekly dynamics of market capitalization of the market segment - Breast cancer
MacroGenics develops innovative antibody-based cancer treatments. The chart below will help investors compare the company's share price volatility, driven by research results, with the overall dynamics of the oncology sector and understand how its scientific breakthroughs differentiate it from its competitors.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
MacroGenics is a biotech company developing cancer therapies. Its shares exist in a world of their own, where research data is king. The chart clearly demonstrates that MGNX's performance is largely uncorrelated with the market, driven by its unique development news.
Market capitalization of the company, segment and market as a whole
MGNX - Market capitalization of the company MacroGenics Inc.
MacroGenics' market capitalization is a financial map of innovation in immuno-oncology. This biotech company's chart reflects investors' faith in its platform for creating next-generation antibodies to fight cancer. Its volatility reflects the complex clinical trials and partnerships with big pharma that shape its future.
MGNX - Share of the company's market capitalization MacroGenics Inc. within the market segment - Breast cancer
MacroGenics' market share in the oncology sector reflects its dual status: the company has both approved drugs and a vast pipeline of developments. Its market weight is a combination of current revenue and the enormous potential of its innovative platforms for developing next-generation cancer drugs.
Market capitalization of the market segment - Breast cancer
MacroGenics develops innovative antibody-based drugs for cancer treatment. The chart below shows the overall market capitalization of the entire oncology sector. Its dynamics reflect the flow of investment and the belief that new technologies will offer more effective treatments.
Market capitalization of all companies included in a broad market index - GURU.Markets
MacroGenics is a biopharmaceutical company developing innovative antibody-based drugs for cancer treatment. Its market capitalization reflects the potential of its scientific platform. The chart below shows the economic weight of companies at the forefront of immuno-oncology.
Book value capitalization of the company, segment and market as a whole
MGNX - Book value capitalization of the company MacroGenics Inc.
For MacroGenics, a biopharmaceutical company, book value is its capital and R&D centers. The chart below shows the material and financial basis for developing innovative cancer drugs. Its dynamics reflect both research investments and payments received from partners.
MGNX - Share of the company's book capitalization MacroGenics Inc. within the market segment - Breast cancer
MacroGenics is a biotech company developing innovative antibodies for cancer treatment. Its main asset is its scientific platform. Along with R&D, the company also has manufacturing capabilities. The chart below shows how its physical infrastructure supports both research and potential drug production.
Market segment balance sheet capitalization - Breast cancer
MacroGenics is a biotech company. Unlike many "light" startups, it has not only R&D centers but also its own manufacturing facilities, making it more capital-intensive. The graph will show whether such vertical integration is the norm for the entire biopharmaceutical industry.
Book value of all companies included in the broad market index - GURU.Markets
MacroGenics' balance sheet consists of a scientific platform for creating bispecific antibodies for cancer treatment and manufacturing facilities for their production. The company's assets represent the capital invested in this complex technology, capable of simultaneously attacking cancer cells from two angles. The chart shows its scientific strength.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - MacroGenics Inc.
MacroGenics develops innovative antibodies for cancer treatment. Its balance sheet represents cash flow for research, and its market capitalization represents the valuation of its DART scientific platform, which is capable of creating complex bispecific molecules. The chart shows how investors assess the potential of this technology for creating more effective oncology drugs.
Market to book capitalization ratio in a market segment - Breast cancer
MacroGenics is a biopharmaceutical company developing antibodies for cancer treatment. Its value is determined by its pipeline of drugs at various stages of development. This chart demonstrates the premium the market is willing to pay for its scientific platform and potential blockbusters compared to its tangible assets.
Market to book capitalization ratio for the market as a whole
MacroGenics is a biotech company developing innovative antibody-based cancer treatments. The chart shows how the market values its scientific platform. The company's market capitalization is a combination of revenue from its approved drug and investor confidence in the potential of its extensive pipeline, creating a high premium for its assets.
Debts of the company, segment and market as a whole
MGNX - Company debts MacroGenics Inc.
MacroGenics is a biopharmaceutical company developing innovative antibody-based cancer treatments. Expensive clinical trials and research require a constant influx of capital. This chart shows how the company uses financial instruments, including debt, to advance its broad portfolio of oncology drugs.
Market segment debts - Breast cancer
MacroGenics is a biopharmaceutical company developing innovative cancer treatments based on monoclonal antibodies. Their technology platform enables the creation of complex protein drugs. The chart shows common financial metrics for the pharmaceutical industry, which can be used to assess how MacroGenics funds its extensive and expensive research portfolio.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio MacroGenics Inc.
MacroGenics develops innovative antibodies for cancer treatment. The path from idea to a finished drug in oncology is long and extremely expensive. This chart shows the company's reliance on borrowed funds to finance its clinical trials. It provides insight into its financial stability and risks amid the highly competitive sector.
Market segment debt to market segment book capitalization - Breast cancer
Developing complex bispecific antibodies for cancer treatment, like MacroGenics', is at the cutting edge of oncology. This chart shows how the biotech sector funds its expensive R&D. It allows us to appreciate how MacroGenics' financial model, with its proprietary technology platform, differs from other immuno-oncology companies.
Debt to book value of all companies in the market
MacroGenics develops innovative antibody-based cancer treatments. Biotech research is a marathon that requires constant funding. The chart shows how the debt burden adopted to fund breakthrough research fits into the overall market situation and debt capacity.
P/E of the company, segment and market as a whole
P/E - MacroGenics Inc.
This chart for MacroGenics, Inc., a biopharmaceutical company developing cancer treatments, shows its market valuation. The metric reflects how investors view its portfolio of approved products and their confidence in the success of its numerous developments in various stages of clinical trials.
P/E of the market segment - Breast cancer
This indicator represents the average valuation for the biotech sector in which MacroGenics operates. It reflects the overall level of investor optimism regarding scientific breakthroughs in oncology. The chart provides a benchmark for understanding how the market evaluates MacroGenics' development portfolio relative to the broader industry.
P/E of the market as a whole
MacroGenics develops innovative antibody-based drugs for cancer treatment. The company has both an approved product and a pipeline of promising developments. This chart reflects the market's risk appetite in biotech. It helps understand how the market balances the valuation of stable sales revenues with the potential for future blockbusters, and how this relates to overall sentiment in the sector.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company MacroGenics Inc.
MacroGenics is a biotech company developing innovative monoclonal antibodies for cancer treatment. Its future depends on the commercial success of its currently approved drug and the results of trials of other candidates in its pipeline. This chart shows how investors assess the potential of its scientific platform and its ability to bring new cancer immunotherapies to market.
%20P%2FE%20MacroGenics%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-MacroGenics-Inc.&v=1772631288353 "Chart of the company's future (projected) P/E MacroGenics Inc.")
Future (projected) P/E of the market segment - Breast cancer
MacroGenics is a biotech company developing innovative monoclonal antibodies for cancer treatment. The company uses its proprietary platforms to create more effective drugs. This chart reflects expectations for the biotech sector, helping to assess how highly the market values MacroGenics' scientific technologies and clinical pipeline.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Breast%20cancer&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Breast-cancer&v=1772631288361 "Future (projected) P/E graph of the market segment - Breast cancer")
Future (projected) P/E of the market as a whole
MacroGenics is a biotech company developing innovative antibody-based drugs for cancer treatment. Their work requires significant investment in R&D. This graph of overall expectations demonstrates the market's willingness to fund research-intensive projects. Investor optimism facilitates raising capital for expensive clinical trials that could lead to the development of new drugs.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772631288366 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit MacroGenics Inc.
MacroGenics is a biopharmaceutical company developing monoclonal antibodies for cancer treatment. This chart shows financial results, which can be volatile. While revenue may come from licensing fees from partners and sales of approved drugs, the company also incurs high clinical trial costs for its extensive pipeline.
Profit of companies in the market segment - Breast cancer
Asia Pacific Wire & Cable is a manufacturer of wires and cables for the telecommunications and energy industries in the Asia-Pacific region. The company's profitability depends on infrastructure investments. This chart shows how electrification and communications network development projects in developing countries are creating stable demand for basic products like cables.
Overall market profit
MacroGenics is a biotech company developing innovative monoclonal antibody-based drugs for the treatment of cancer. Its success depends on clinical trial results and regulatory approval. This total corporate profitability chart provides a backdrop for assessing how scientific breakthroughs in oncology create value regardless of market cycles.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company MacroGenics Inc.
MacroGenics is a biotech company developing monoclonal antibodies for cancer treatment. Its revenue forecast depends on sales of its approved drug, Margenza, and the success of its extensive clinical development pipeline. This chart shows analyst expectations for the commercial potential of the company's current and future oncology drugs.
%20profit%20of%20the%20company%20MacroGenics%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-MacroGenics-Inc.&v=1772631288443 "Graph of future (projected) profit of the company MacroGenics Inc.")
Future (predicted) profit of companies in the market segment - Breast cancer
MacroGenics develops innovative monoclonal antibodies for cancer treatment. The company's technological platforms enable the creation of more effective drugs that target the immune system. This chart shows profitability forecasts for the oncology sector. It reflects expectations for the next generation of immunotherapy, in which MacroGenics aims to become a leader.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Breast%20cancer&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Breast-cancer&v=1772631288456 "Graph of future (predicted) profits of companies in a market segment - Breast cancer")
Future (predicted) profit of the market as a whole
MacroGenics develops innovative antibody-based cancer treatments. Like many biotech companies, its valuation is driven by research results. However, the overall economic outlook reflected in this chart is critically important, as it influences investor risk appetite and the evaluation of potential M&A deals with major pharma companies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772631288469 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - MacroGenics Inc.
MacroGenics is a biotech company specializing in the development of innovative monoclonal antibodies for cancer treatment. The company has one approved drug and several in development. The chart shows how investors value its revenue, weighing current sales against the huge potential revenue from future drugs if they prove successful.
P/S market segment - Breast cancer
MacroGenics, Inc. is a biopharmaceutical company that develops and commercializes innovative monoclonal antibodies for the treatment of cancer. The company has both an approved drug and an extensive clinical development pipeline. This chart shows the average valuation in the sector, allowing one to assess how the market values MacroGenics' current and future revenue.
P/S of the market as a whole
MacroGenics is a biopharmaceutical company developing innovative monoclonal antibody-based therapies for cancer treatment. Its portfolio includes both commercial products and developments in the clinical trials stage. This chart, showing average valuations, helps us understand the premium the market places on the revenue of a biotech company with its own scientific platform.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company MacroGenics Inc.
MacroGenics develops and commercializes innovative monoclonal antibodies for the treatment of cancer. This chart reflects investor expectations regarding the future success of its drug portfolio. The valuation is based on sales forecasts for already approved drugs and the potential of its extensive pipeline of candidates in various stages of clinical trials.
%20P%2FS%20MacroGenics%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-MacroGenics-Inc.&v=1772631288562 "The graph of the company's future (projected) P/S MacroGenics Inc.")
Future (projected) P/S of the market segment - Breast cancer
MacroGenics is a biopharmaceutical company developing innovative monoclonal antibodies for cancer treatment. Its technology platforms enable the creation of more effective immunotherapeutic drugs. The chart shows the premium investors are willing to pay for MacroGenics' future sales, reflecting the potential of its scientific pipeline.
%20P%2FS%20market%20segment%20graph%20-%20Breast%20cancer&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Breast-cancer&v=1772631288599 "Future (projected) P/S market segment graph - Breast cancer")
Future (projected) P/S of the market as a whole
Investor optimism about future revenues hinges on innovative approaches to cancer treatment. MacroGenics is developing bispecific antibodies that can simultaneously attack cancer cells and activate the immune system. Their sophisticated scientific platform reflects the market's belief that new immunotherapy technologies will lead to more effective treatments.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772631288637 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales MacroGenics Inc.
MacroGenics is a biopharmaceutical company developing innovative antibody-based therapies for cancer treatment. Its revenue is generated from sales of its approved drug, Margenza, as well as from payments from large pharmaceutical co-development partners. This chart shows its progression from the research to the commercial stage.
Sales of companies in the market segment - Breast cancer
MacroGenics is a biopharmaceutical company developing innovative monoclonal antibodies for cancer treatment. Its platform enables the creation of drugs that simultaneously attack multiple targets. This graph shows the total revenue of the breast cancer drug market, highlighting the enormous potential for companies that offer smarter and more effective approaches to therapy.
Overall market sales
MacroGenics is a biopharmaceutical company developing innovative monoclonal antibodies for cancer treatment. The company has both an approved drug and a pipeline of new developments. Its success depends on commercial sales and research results. This overall economic situation impacts healthcare budgets, which determine the availability of expensive oncology drugs.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company MacroGenics Inc.
MacroGenics is a biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer. The company has one approved drug and several candidates in development. This chart shows analyst revenue expectations, reflecting their sales forecasts for the current drug and the likelihood of success for future developments.
%20sales%20of%20the%20company%20MacroGenics%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-MacroGenics-Inc.&v=1772631288693 "Schedule of future (projected) sales of the company MacroGenics Inc.")
Future (projected) sales of companies in the market segment - Breast cancer
MacroGenics is a biopharmaceutical company developing innovative monoclonal antibodies for cancer treatment. Its platform enables the creation of drugs that target multiple targets simultaneously. This chart shows projected sales for the entire breast cancer drug segment, allowing one to assess the growth potential analysts are predicting for this industry.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Breast%20cancer&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Breast-cancer&v=1772631288722 "Schedule of future (projected) sales of companies in the market segment - Breast cancer")
Future (projected) sales of the market as a whole
MacroGenics is a biopharmaceutical company developing innovative monoclonal antibodies for cancer treatment. Its success depends on the results of clinical trials and partnerships with major pharmaceutical companies. This overall economic activity schedule influences the investment climate in the biotech sector, determining the availability of capital to continue expensive development.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772631288751 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality MacroGenics Inc.
MacroGenics is a biotech company developing innovative antibody-based therapies for cancer treatment. This metric reflects its financial strategy, demonstrating how the company balances revenue from approved drugs with significant investments in an extensive clinical trial pipeline for future growth.
Market segment marginality - Breast cancer
MacroGenics is a biopharmaceutical company developing innovative monoclonal antibodies for cancer treatment. Profitability depends on the success of its platform and the commercialization of its drugs. This chart shows the operational efficiency of its R&D model and cost structure compared to other companies working in the oncology field.
Market marginality as a whole
MacroGenics is a biopharmaceutical company developing innovative monoclonal antibodies for cancer treatment. Their platform enables the creation of drugs that target multiple targets simultaneously. The company's success depends on clinical trials. This overall profitability profile is important to them given the overall investor appetite for risky biotech assets.
Employees in the company, segment and market as a whole
Number of employees in the company MacroGenics Inc.
MacroGenics is a biotech company with both approved cancer drugs and a pipeline of developments. This graph demonstrates a more mature organization compared to purely research-based firms. Its staff includes not only scientists but also manufacturing specialists and a commercial team, reflecting the full cycle of drug development and sales.
Share of the company's employees MacroGenics Inc. within the market segment - Breast cancer
MacroGenics is developing innovative monoclonal antibodies for cancer treatment. This chart shows the percentage of leading immunologists and oncologists involved in antibody bioengineering that the company attracts. Its team is at the forefront of developing the next generation of targeted cancer therapies.
Number of employees in the market segment - Breast cancer
MacroGenics, Inc. is a biotechnology company specializing in the development and commercialization of innovative monoclonal antibodies for cancer treatment. This chart shows overall employment in the oncology sector. It illustrates the intensity of research and the intense competition to develop new immunotherapeutic drugs for various types of cancer.
Number of employees in the market as a whole
MacroGenics develops and commercializes innovative monoclonal antibodies for cancer treatment. Its biotech platform enables the creation of complex drugs that require a robust scientific foundation. This employment chart also includes research-intensive companies where growth in the number of scientists and clinicians directly correlates with progress in the fight against cancer.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company MacroGenics Inc. (MGNX)
MacroGenics, Inc. is a biopharmaceutical company developing innovative antibody-based drugs for cancer treatment. This chart demonstrates a high valuation of intellectual capital. As with most biotech companies, the valuation per employee is very high because investors evaluate the potential of a unique scientific platform and development pipeline, rather than current operations.
%20of%20the%20company%20MacroGenics%20Inc.%20(MGNX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-MacroGenics-Inc.-MGNX&v=1772631288988 "Chart of market capitalization per employee (in thousands of dollars) of the company MacroGenics Inc. (MGNX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Breast cancer
MacroGenics is a biotech company developing innovative antibody-based cancer treatments. Their key asset is their scientific platform and development pipeline. This metric demonstrates the premium the market is willing to pay for their intellectual property per researcher. A high value reflects high expectations for the commercial success of their future drugs.
%20by%20market%20segment%20-%20Breast%20cancer&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Breast-cancer&v=1772631289020 "Market capitalization per employee (in thousands of dollars) by market segment - Breast cancer")
Market capitalization per employee (in thousands of dollars) for the overall market
MacroGenics, Inc. is a biopharmaceutical company developing innovative antibody-based cancer treatments. Its valuation is driven by a broad portfolio of clinical and preclinical programs. Its per-employee valuation reflects the value of a scientific platform capable of generating multiple drug candidates, rather than relying on a single product.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772631289038 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company MacroGenics Inc. (MGNX)
MacroGenics is a biotech company with both an approved cancer drug (Margenza) and an extensive R&D pipeline. It's a hybrid model. This chart shows the net result: it measures how much sales revenue covers the company's massive R&D costs, and how much net profit (or loss) accrues per employee.
%20Chart%20MacroGenics%20Inc.%20(MGNX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-MacroGenics-Inc.-MGNX&v=1772631289064 "Company Profit Per Employee (in thousands of dollars) Chart MacroGenics Inc. (MGNX)")
Profit per employee (in thousands of dollars) in the market segment - Breast cancer
MacroGenics is a biotech company that already has one approved drug, but its primary focus remains on R&D. This chart shows the benchmark they strive to achieve. Their efficiency is a balance between sales revenue and the enormous costs of clinical research. The goal is to grow sales faster than the costs of developing new drugs.
%20in%20the%20market%20segment%20-%20Breast%20cancer&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Breast-cancer&v=1772631289104 "Chart of profit per employee (in thousands of dollars) in the market segment - Breast cancer")
Profit per employee (in thousands of dollars) for the market as a whole
MacroGenics (MGNX) is a biopharmaceutical company developing antibody-based cancer treatments. They have both a commercial product and an extensive R&D pipeline. This chart shows the balance. Profit per employee here is the result of the struggle between sales revenue and the enormous costs of clinical trials of new drugs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772631289165 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee MacroGenics Inc. (MGNX)
For MacroGenics, a biotech company developing antibodies for cancer treatment, this chart shows progress in commercializing its research. The increase in revenue per employee reflects successful sales of already approved drugs and receipt of payments from co-development partners.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-MacroGenics-Inc.-MGNX&v=1772631289177 "Sales chart per company employee MacroGenics Inc. (MGNX)")
Sales per employee in the market segment - Breast cancer
MacroGenics is a biopharmaceutical company developing antibodies for cancer treatment, including the already approved drug Margenza. This metric reflects the average revenue per employee for the segment. It allows us to assess how productive MacroGenics' R&D and commercialization team is in monetizing its technologies compared to other oncology biotechs.
Sales per employee for the market as a whole
MacroGenics (MGNX) is a biopharmaceutical company developing immunotherapies for cancer treatment. They have both approved drugs and an extensive R&D pipeline. This metric reflects their hybrid model. The increase in revenue per employee reflects increased sales of approved drugs and the receipt of partner payments (milestones) for the development of new candidates.
Short shares by company, segment and market as a whole
Shares shorted by company MacroGenics Inc. (MGNX)
MacroGenics is a biotech company developing antibodies for cancer treatment. It has one approved drug, but its primary focus is R&D. Its developments face intense competition in the immuno-oncology field. This chart reflects investor bets that its drug candidates will fail to outperform existing treatment standards or will fail in trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-MacroGenics-Inc.-MGNX&v=1772631289258 "Short Shares Chart for the Company MacroGenics Inc. (MGNX)")
Shares shorted by market segment - Breast cancer
MacroGenics (MGNX) is a biopharmaceutical company developing innovative antibody-based drugs for the treatment of cancer, including breast cancer. This chart shows the aggregate short positions across the entire oncology biotech sector. It reflects the general investor skepticism regarding the high risk and cost of development in this field.
Shares shorted by the overall market
MacroGenics (MGNX) is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing MGNX will be unable to raise capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator MacroGenics Inc. (MGNX)
MacroGenics is a biotech company balancing sales of its approved drug (Margenza) with hopes for its R&D platform. This chart measures which is more important in the eyes of investors. It shows when the stock is overbought on good R&D news or oversold on weak sales reports.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-MacroGenics-Inc.-MGNX&v=1772631289340 "RSI 14 indicator chart for the company's stock MacroGenics Inc. (MGNX)")
RSI 14 Market Segment - Breast cancer
MacroGenics (MGNX) are antibody "engineers." Their platform (DART) creates bispecific ("two-armed") antibodies to attack cancer (especially breast cancer). The "Breast Cancer" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand: is MGNX's growth due to their R&D, or is the entire biotech sector "overheated"?
RSI 14 for the overall market
MacroGenics (MGNX) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast MGNX (MacroGenics Inc.)
MacroGenics is a biopharmaceutical company developing innovative immuno-oncology drugs (including bispecific antibodies) for the treatment of cancer. This chart shows the average target price from analysts, which is almost entirely based on their assessment of the clinical data and the commercial potential of the R&D portfolio.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-MGNX-MacroGenics-Inc.&v=1772631289411 "A chart showing analyst consensus forecasts for the expected stock price. MGNX (MacroGenics Inc.)")
The difference between the consensus estimate and the actual stock price MGNX (MacroGenics Inc.)
MacroGenics is a biotech company specializing in the development of innovative antibodies (the DART platform) for cancer treatment. This chart shows how far the current stock price differs from the "fair" value predicted by analysts. For such an R&D company, this gap reflects the experts' confidence in the success of their clinical pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-MGNX-MacroGenics-Inc.&v=1772631289447 "A chart showing the difference between the consensus forecast and the actual stock price. MGNX (MacroGenics Inc.)")
Analyst consensus forecast for stock prices by market segment - Breast cancer
MacroGenics is a biotech company developing a new generation of immunotherapy (the DART platform) for the treatment of cancer, primarily breast cancer (Margenza). This chart shows analysts' overall expectations for the entire oncology sector. It reflects whether experts believe in new R&D breakthroughs or consider the sector too risky.
Analysts' consensus forecast for the overall market share price
MacroGenics is a biotech company specializing in the development of innovative drugs (antibodies) for the treatment of cancer, particularly breast cancer. This is a high-risk sector. This chart reflects the overall risk appetite in the market. For MacroGenics, the overall optimism of analysts (the rising chart) is critical for attracting the capital needed to fund expensive research.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index MacroGenics Inc.
MacroGenics is a biotech company focused on immuno-oncology. Their signature product is DART, a platform for creating bispecific antibodies that target the immune system to cancer. This graph represents an R&D bet. It weighs the commercial success of their (very niche) first drug (Margenza) against the enormous but high-risk potential of the rest of their research pipeline.
AKIMA Market Segment Index - Breast cancer
MacroGenics develops innovative antibody-based oncology drugs, including DART molecules that can attack multiple targets simultaneously. This chart shows the average index for the oncology sector. It provides investors with a benchmark for how MacroGenics, with its sophisticated scientific platform, compares to the sector average.
The AKIM Index for the overall market
MacroGenics is a biopharmaceutical company developing antibodies for the treatment of cancer (including breast cancer). It has partnerships with pharma giants. This chart, which reflects the market average, is an indicator of risk appetite. It provides a macro backdrop that is critical for assessing the prospects of this scientific platform and its ability to attract funding.
